Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost cl...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2059053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832088403566395392 |
|---|---|
| author | Andrew Blauvelt Mark Boguniewicz Patrick M. Brunner Paula C. Luna Pinaki Biswas Marco DiBonaventura Saleem A. Farooqui Ricardo Rojo Michael C. Cameron |
| author_facet | Andrew Blauvelt Mark Boguniewicz Patrick M. Brunner Paula C. Luna Pinaki Biswas Marco DiBonaventura Saleem A. Farooqui Ricardo Rojo Michael C. Cameron |
| author_sort | Andrew Blauvelt |
| collection | DOAJ |
| description | Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated.Results Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo.Conclusion Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.ClinicalTrials.gov NCT02780167, NCT03349060, NCT03575871 |
| format | Article |
| id | doaj-art-45ab61016389422f887a6047d9ec6fe2 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-45ab61016389422f887a6047d9ec6fe22025-02-05T19:02:56ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-07-013352605261310.1080/09546634.2022.2059053Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of lifeAndrew Blauvelt0Mark Boguniewicz1Patrick M. Brunner2Paula C. Luna3Pinaki Biswas4Marco DiBonaventura5Saleem A. Farooqui6Ricardo Rojo7Michael C. Cameron8Department of Dermatology, Oregon Medical Research Center, Portland, OR, USADivision of Allergy and Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, CO, USADepartment of Dermatology, Medical University of Vienna, Vienna, Austria, and Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USADermatology Department, Hospital Alemán, Buenos Aires, ArgentinaPfizer Inc, New York, NY, USAPfizer Inc, New York, NY, USAPfizer R&D UK Ltd, Sandwich, UKPfizer Inc, Groton, CT, USAPfizer Inc, New York, NY, USABackground Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated.Results Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo.Conclusion Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.ClinicalTrials.gov NCT02780167, NCT03349060, NCT03575871https://www.tandfonline.com/doi/10.1080/09546634.2022.2059053Atopic dermatitiseczemapruritusquality of life |
| spellingShingle | Andrew Blauvelt Mark Boguniewicz Patrick M. Brunner Paula C. Luna Pinaki Biswas Marco DiBonaventura Saleem A. Farooqui Ricardo Rojo Michael C. Cameron Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life Journal of Dermatological Treatment Atopic dermatitis eczema pruritus quality of life |
| title | Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life |
| title_full | Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life |
| title_fullStr | Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life |
| title_full_unstemmed | Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life |
| title_short | Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life |
| title_sort | abrocitinib monotherapy in investigator s global assessment nonresponders improvement in signs and symptoms of atopic dermatitis and quality of life |
| topic | Atopic dermatitis eczema pruritus quality of life |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2022.2059053 |
| work_keys_str_mv | AT andrewblauvelt abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT markboguniewicz abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT patrickmbrunner abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT paulacluna abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT pinakibiswas abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT marcodibonaventura abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT saleemafarooqui abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT ricardorojo abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife AT michaelccameron abrocitinibmonotherapyininvestigatorsglobalassessmentnonrespondersimprovementinsignsandsymptomsofatopicdermatitisandqualityoflife |